These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 22251181)

  • 1. Delayed effects in the exposure-response analysis of clinical QTc trials.
    Glomb P; Ring A
    J Biopharm Stat; 2012; 22(2):387-400. PubMed ID: 22251181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exposure-response modeling approach for assessing QT effect in "thorough" QT/QTc studies.
    Hosmane B; Locke C; Chiu YL
    J Biopharm Stat; 2010 May; 20(3):615-31. PubMed ID: 20358440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statistical issues including design and sample size calculation in thorough QT/QTc studies.
    Zhang J; Machado SG
    J Biopharm Stat; 2008; 18(3):451-67. PubMed ID: 18470755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sample size, power calculations, and their implications for the cost of thorough studies of drug induced QT interval prolongation.
    Malik M; Hnatkova K; Batchvarov V; Gang Y; Smetana P; Camm AJ
    Pacing Clin Electrophysiol; 2004 Dec; 27(12):1659-69. PubMed ID: 15613131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statistical issues of QT prolongation assessment based on linear concentration modeling.
    Tsong Y; Shen M; Zhong J; Zhang J
    J Biopharm Stat; 2008; 18(3):564-84. PubMed ID: 18470764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Oct; 70(202):61134-5. PubMed ID: 16237860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic and concentration--QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies.
    Florian JA; Tornøe CW; Brundage R; Parekh A; Garnett CE
    J Clin Pharmacol; 2011 Aug; 51(8):1152-62. PubMed ID: 21228407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical analysis methods for QT/QTc prolongation.
    Ma H; Smith B; Dmitrienko A
    J Biopharm Stat; 2008; 18(3):553-63. PubMed ID: 18470763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple comparisons of repeated measured response: issues of assessment of prolongation of QT interval in thorough QT trials.
    Tsong Y; Zhong J
    J Biopharm Stat; 2010 May; 20(3):604-14. PubMed ID: 20358439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sample size and power estimation in "thorough" QT/QTc studies with parallel group design.
    Hosmane B; Locke C; Chiu YL
    J Biopharm Stat; 2010 May; 20(3):578-86. PubMed ID: 20358437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drugs, QT interval prolongation and ICH E14: the need to get it right.
    Shah RR
    Drug Saf; 2005; 28(2):115-25. PubMed ID: 15691222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugs, QTc interval prolongation and final ICH E14 guideline : an important milestone with challenges ahead.
    Shah RR
    Drug Saf; 2005; 28(11):1009-28. PubMed ID: 16231954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is a thorough QTc study necessary? The role of modeling and simulation in evaluating the QTc prolongation potential of drugs.
    Rohatagi S; Carrothers TJ; Kuwabara-Wagg J; Khariton T
    J Clin Pharmacol; 2009 Nov; 49(11):1284-96. PubMed ID: 19734373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development.
    Salvi V; Karnad DR; Panicker GK; Kothari S
    Br J Pharmacol; 2010 Jan; 159(1):34-48. PubMed ID: 19775279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of six commonly used QT correction models and their parameter estimation methods.
    Wang D; Taubel J; Arezina R
    J Biopharm Stat; 2012; 22(6):1148-61. PubMed ID: 23075014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statistical assessment of QT/QTc prolongation based on maximum of correlated normal random variables.
    Cheng B; Chow SC; Burt D; Cosmatos D
    J Biopharm Stat; 2008; 18(3):494-501. PubMed ID: 18470758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline.
    Darpo B; Nebout T; Sager PT
    J Clin Pharmacol; 2006 May; 46(5):498-507. PubMed ID: 16638733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings.
    Noel GJ; Goodman DB; Chien S; Solanki B; Padmanabhan M; Natarajan J
    J Clin Pharmacol; 2004 May; 44(5):464-73. PubMed ID: 15102866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of baseline measurement on the change from baseline in QTc intervals.
    Tian H; Natarajan J
    J Biopharm Stat; 2008; 18(3):542-52. PubMed ID: 18470762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Literature review and pilot studies of the effect of QT correction formulas on reported beta2-agonist-induced QTc prolongation.
    Milic M; Bao X; Rizos D; Liu F; Ziegler MG
    Clin Ther; 2006 Apr; 28(4):582-90. PubMed ID: 16750469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.